Atara Biotherapeutics Inc. (NASDAQ:ATRA) Director Carol Giltner Gallagher sold 1,184 shares of the stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $19.35, for a total value of $22,910.40. Following the transaction, the director now directly owns 99,377 shares of the company’s stock, valued at $1,922,944.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded down 2.45% during trading on Friday, hitting $17.90. The stock had a trading volume of 51,074 shares. The company’s 50 day moving average price is $16.89 and its 200 day moving average price is $19.55. The company’s market capitalization is $516.59 million. Atara Biotherapeutics Inc. has a 52 week low of $12.45 and a 52 week high of $40.80.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Friday, November 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by $0.10. Analysts predict that Atara Biotherapeutics Inc. will post ($3.05) earnings per share for the current year.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC increased its position in Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock worth $108,000 after buying an additional 4,600 shares during the period. Panagora Asset Management Inc. acquired a new position in shares of Atara Biotherapeutics during the third quarter worth $110,000. BlackRock Group LTD increased its position in shares of Atara Biotherapeutics by 3.7% in the third quarter. BlackRock Group LTD now owns 5,532 shares of the company’s stock worth $119,000 after buying an additional 198 shares during the last quarter. BlackRock Inc. increased its position in shares of Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock worth $137,000 after buying an additional 5,019 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock worth $148,000 after buying an additional 6,467 shares during the last quarter. Institutional investors and hedge funds own 74.91% of the company’s stock.

Several analysts have issued reports on ATRA shares. Canaccord Genuity set a $47.00 price objective on Atara Biotherapeutics and gave the company a “buy” rating in a research note on Sunday, November 6th. Zacks Investment Research lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 26th. Jefferies Group started coverage on Atara Biotherapeutics in a research note on Monday, October 24th. They issued a “buy” rating and a $23.00 price objective on the stock. Goldman Sachs Group Inc. lowered Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $23.00 to $16.00 in a research note on Thursday, September 15th. Finally, Citigroup Inc. upped their price objective on Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a research note on Friday, August 19th. Three analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $25.86.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.